A combination approach using rizatriptan (targeting CGRP-related nociception) and meloxicam (blocking COX-2 inflammation) may improve migraine treatment by addressing two key pathways simultaneously.
~1 billion affectedglobally by migraine, highlighting the need for more effective treatments targeting both CGRP nociception and COX-mediated inflammation
What the researchers found
The study presents the rationale and evidence for SYMBRAVO, a dual-pathway pharmacological approach combining rizatriptan (a triptan targeting CGRP-induced nociception via serotonin 5-HT1B/1D receptors) and meloxicam (a selective COX-2 inhibitor reducing inflammatory prostaglandins).
The authors argue that CGRP and COX pathways interact in migraine through neuroinflammatory crosstalk, where CGRP-mediated neurogenic inflammation amplifies COX-dependent prostaglandin production and vice versa. Targeting both simultaneously could improve efficacy, reduce the dose needed for each drug, and minimize side effects compared to monotherapy.
Why it matters
Despite available treatments, many migraine patients still experience inadequate relief. Single-drug approaches often fail because migraine involves multiple interconnected pathways. This combination strategy targeting both CGRP-mediated pain and COX-mediated inflammation could represent a more effective treatment paradigm, particularly for patients who don't respond well to triptans or NSAIDs alone.
How the study worked
This is a review and pharmacological analysis that explores the molecular basis, drug interactions, and clinical potential of combining rizatriptan and meloxicam for migraine. The authors examine the neuroinflammatory crosstalk between CGRP and COX pathways and assess how dual targeting could overcome limitations of single-drug approaches.
What this study cannot tell us
The abstract does not present original clinical trial data or specific efficacy outcomes for the SYMBRAVO combination. This appears to be primarily a review and pharmacological rationale rather than a clinical study with patient data. The specific synergistic benefit of this combination versus other drug pairings needs clinical validation.
How to read the evidence
This is a pharmacological review and analysis rather than a clinical trial. It provides a scientific rationale for combination therapy but does not present original clinical outcome data to demonstrate the approach's efficacy.
When this study was published
Published in 2025, this review addresses the current landscape of migraine pharmacotherapy and the growing recognition that multi-pathway approaches may be needed for effective treatment.
The bigger picture
This work reflects a broader shift in migraine treatment toward multi-target strategies. As the role of CGRP in migraine has become clearer, there is growing interest in how it interacts with other inflammatory pathways. Combination therapies could offer better outcomes than sequential monotherapy trials, which is how many patients are currently managed.
Questions still open
- How does the rizatriptan-meloxicam combination compare in clinical trials to each drug used alone?
- Would this combination approach work for patients who don't respond to newer CGRP-targeted therapies like gepants or monoclonal antibodies?
- What are the long-term safety implications of regularly combining a triptan with an NSAID?
Common questions
What is CGRP and how does it cause migraine pain?
Why combine two different migraine drugs instead of using one?
Read the original research
Neuroinflammatory crosstalk in migraine: consolidated activity of rizatriptan and meloxicam in suppressing CGRP-induced nociception and COX-mediated inflammation.
Inflammopharmacology, 33(7), 3871-3883
Citation
Bhatia, Vandana; Vikram, Vir; Rattan, Aditya; Chandel, Anjali; Ashawat, M S. (2025). Neuroinflammatory crosstalk in migraine: consolidated activity of rizatriptan and meloxicam in suppressing CGRP-induced nociception and COX-mediated inflammation.. Inflammopharmacology, 33(7), 3871-3883. https://doi.org/10.1007/s10787-025-01848-1